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Abstract: While coding variants often have pleiotropic effects across multiple tissues, 
non-coding variants are thought to mediate their phenotypic effects by specific tissue and 
temporal regulation of gene expression. Here, we dissected the genetic and functional 
architecture of a genomic region within the FTO gene that is strongly associated with 
obesity risk. We show that multiple variants on a common haplotype modify the 
regulatory properties of several enhancers targeting IRX3 and IRX5 from megabase 
distances. We demonstrate that these enhancers impact gene expression in multiple 
tissues, including adipose and brain, and impart regulatory effects during a restricted 
temporal window. Our data indicate that the genetic architecture of disease-associated 
loci may involve extensive pleiotropy, allelic heterogeneity, shared allelic effects across 
tissues, and temporally-restricted effects. 
 
One Sentence Summary: The genetic architecture of loci associated with human traits 
implicate pleiotropy, allelic heterogeneity and temporal-specific effects. 
 
Main Text: Although genome-wide association studies (GWAS) have contributed 
extensively to complex disease mapping, our understanding of the genetic architecture 
and molecular mechanisms underlying most disease associations remains incomplete (1, 
2). Recent studies suggest pervasive pleiotropy of regulatory variants modulating gene 
expression across multiple tissues, impacting seemingly disparate disease phenotypes (3, 
4). We set out to dissect the genetic architecture and phenotypic implications of a well-
studied locus associated with human obesity. GWAS have identified common variants in 




effort has been directed towards identifying the causal variant, gene, and tissues 
underlying this association. The associated region is within a large topologically 
associated domain (TAD) of approximately 2 Mb encompassing FTO, RPGRIP1L, and 
the IRXB cluster (including IRX3, IRX5, and IRX6) (6). As a consequence of this 
arrangement, the obesity-associated variants could impact the regulation of any or all of 
these genes. In fact, most of these genes have been independently implicated in body 
weight management phenotypes, leading to additional controversy within the field as to 
which of these genes mediate the genetic association with obesity (7–10). In addition, 
while compelling evidence implicates central nervous system phenotype such as food 
preference and feeding behavior underlying the association with body mass index (BMI) 
(5, 11) alternative models involving altered thermogenesis, autonomous to adipose tissue, 
have also been put forth as putative mechanisms (7, 8). To address these discrepancies, 
we applied an integrated approach to mechanistically dissect the genetic and functional 
architecture of the obesity GWAS signal emanating from the FTO locus.  
To ascertain the pattern of long-range genomic interactions in the locus, we generated a 
comprehensive chromatin interaction map in cell types relevant to obesity. We performed 
in situ promoter capture Hi-C (PCHi-C) in human SGBS preadipocytes and in 
hypothalamic arcuate-like neurons derived from human induced pluripotent stem cells 
(hiPSCs). PCHi-C contact maps from both cell types, and additional 4C-seq data, 
revealed long-range interactions between the obesity-associated locus and promoters of 
IRX3 and IRX5, but not those of IRX6 or FTO/RPGRIP1L (Fig. 1A and fig. S1A). Similar 
results were obtained from a enhancer capture Hi-C dataset in primary human pre-




mice (fig. S1B), we engineered a mouse model (mmFtoΔ20) harboring a 20,204 bp 
deletion spanning the orthologous obesity-associated interval in Fto (fig. S1C). Using 
fluorescence in situ hybridization (FISH) as an orthogonal assay to PCHi-C, we 
interrogated the 3D organization of this region in vivo, in mouse brains from mmFtoΔ20 
heterozygous animals. Designing fosmid-based probes for regions encompassing the 
Fto/Rpgrip1l, Irx3, Irx5, Irx6 promoters, and the Fto obesity-associated locus, as well 
as the region directly adjacent to the 20 kb deletion (Fig. 1B, fig. S2B), we determined 
the pattern of interactions between the obesity-associated region and genes in the Fto-
Irxb locus. Consistent with our PCHi-C and 4C-seq results, FISH data from WT alleles 
in cerebellum revealed significantly increased colocalization (≤200 nm) of the Irx3 and 
Irx5 promoters with the Fto obesity-associated interval in WT alleles, compared with 
deletion alleles and cortex cells that do not express Irx3 and Irx5. We obtained similar 
colocalization data in lung cells, supporting our previous observations that the obesity-
associated interval harbors lung enhancers (7). Conversely, the 20 kb deletion had no 
impact on the distance between the Fto/Rpgri1L or Irx6 promoters and the Fto obesity-
associated interval (Fig. 1C and D, fig. S2C). These observations support a model of 
chromatin compaction at this locus with the obesity-associated region physically 
interacting with both IRX3 and IRX5 in humans and mice. 
We next explored the biological relevance of these observations in vivo. We genetically 
engineered germline null (-/-) and heterozygous (+/-) alleles for Irx3, Irx5, and Irx6 in 
mice (fig. S3). At 20 weeks, Irx3-/- animals displayed a 15-20% blunting in weight gain 
compared to the WT control littermates, as well as a reduction of total fat mass (10-15%), 




improved glucose tolerance, mimicking phenotypes we have previously shown (fig. S4A 
to C and fig. S5A, D to G) (7). While the most striking feature of Irx5-/- mice is early 
postnatal lethality, Irx5 heterozygous mice (Irx5+/-) were viable and thrived. Similar to 
Irx3-/-, Irx5+/- mice exhibited an anti-obesity phenotype with 15-20% weight reduction, 
loss of body fat mass (5%), activation of browning in WAT, and improved glucose 
tolerance (fig. S4D to F and fig. S5B, H to K).  Irx6 knockout (Irx6-/-) mice showed none 
of these metabolic phenotypes (fig. S4G to I and fig. S5 C, L to O). Altogether, our in 
vivo mouse models support our chromatin conformation data implicating Irx3 and Irx5, 
but not Irx6, as potentially mediating the genetic association with obesity. 
The phenotypic impact of IRX3 and IRX5 on adipocyte biology has been described (7, 8). 
Specifically, a SNP (rs1421085) modulates IRX3 and IRX5 expression in preadipocytes 
and regulates an adipose thermogenesis program (8). These data, however, do not provide 
an immediate explanation for the well-described association of variants within FTO with 
eating behavior and, more specifically, eating preferences, such as increased caloric 
intake (5, 11, 13). Toward that end, we have previously shown that the hypothalamic 
expression of a dominant-negative IRX3 isoform in mice phenocopies the organismal 
level metabolic phenotypes seen in germline Irx3 null mice (7). To interrogate for the 
impact of Irx3 in molecular and physiological brain phenotypes associated with obesity, 
we performed transcriptomic analysis (RNA-seq) on hypothalami from Irx3-/- mice and 
WT littermates. Gene ontology (GO) enrichment analysis showed that, of the 359 up-
regulated genes, at least 103 are involved in neurodevelopment and cellular processes, 
such as cell communication and synaptic signaling, consistent with the well-known 




database, we investigated GO categories for disease links and found that the top ranked 
diseases associated with these differentially expressed genes are obesity, diabetes, and 
impaired glucose tolerance (Fig. 2A, fig. S6A and B and Table S1), supporting the 
notion that Irx3 expression in brain may coordinate a genetic program involved in 
metabolism. To examine whether Irx3 plays a role in food intake or macronutrient 
preference, we subjected a cohort of adult Irx3-/- and WT control littermates to a series 
of two-bottle choice experiments in which all mice were offered the choice between 
water and a range of nutritive and non-nutritive tastants (17). We found that obesity-
resistant Irx3-/- mice display a reduced preference for sucrose, but not lipid or protein, 
compared to WT animals (Fig. 2B and fig. S6C). Altered sweet preference has not been 
shown as a phenotype in humans harboring risk alleles in the FTO obesity-associated 
region. To test this, we obtained GWAS summary statistics from 118,950 genotyped 
individuals responding to a sweet preference questionnaire from 23andMe (Table S2). A 
GWAS of these data indicated that SNPs within the FTO obesity-associated region 
represent the second strongest association with sweet preference in humans, with the C 
allele of rs1421085 associated with sweet food preference over salty (3.6X10-23, 
OR=1.1) (Fig. 2C). Taken together, our in vivo mouse data establish a central nervous 
system role of Irx3 in the regulation of metabolism and feeding behavior analogous to 
phenotypes associated with allelic variants of obesity-associated SNPs within FTO in 
humans, including alterations in consummatory behavior. Previous work has described 
reciprocal counterregulatory mechanisms between peripheral energy expenditure and 
energy intake, with perturbations in diet and nutritional status inducing long-term 




whether the alterations in feeding behavior in Irx3-/- mice result from primary, 
autonomous dysfunction of regulatory circuits within the central nervous system, 
including the hypothalamus, or are secondary to peripheral effects, through the 
intersection of neuro-hormonal cues from adipose and other peripheral tissues. 
Having uncovered a central nervous system role of Irx3 in metabolism and feeding 
behavior, we next sought to characterize the regulatory potential of obesity-associated 
SNPs within FTO. To functionally classify regulatory variants in neurons and 
adipocytes, thought to represent tissues that participate in the genetics of obesity in 
humans (19), we used orthogonal computational and experimental approaches. For 
computational regulatory variant predictions, we derived multiple variant features from 
sequence-based methods which harness cross-species functional sequence conservation 
and sequence-based regulatory evidence (20). Experimentally, we used a Massively 
Parallel Reporter Assay (MPRA) to identify variants located in enhancers in 
hippocampal (HT22) and preadipocyte (3T3-L1) mouse cell lines. We tested all 87 
common (MAF>=5%) variants in strong linkage disequilibrium (r2>0.8) with the lead 
obesity GWAS associated SNP rs1558902 (19). We found 21 SNPs in 3T3-L1 
preadipocytes and 18 SNPs in HT22 neuronal cells located in enhancers in at least three 
replicates tested in each cell line (Table S3). Of these, 5 SNPs displayed allelic-specific 
enhancer activities in preadipocyte and/or neuronal cells. Each was located in 
independent enhancers spread over 31 kb (Fig. 3A, fig. S7 and Table S4 and S5). Using 
a luciferase reporter assay, we confirmed allele-specific enhancer properties and 
directional effects of 4 variants in preadipocytes, 2 of which changed regulatory activity 




chromatin regions in human adipose and brain tissues, assayed by the Roadmap 
Epigenomics Consortium (Fig. 3A). In addition, we confirmed that all accessible 
variants score highest across multiple, orthogonal sequence-based computational 
metrics, including high functional conservation scores for the variant flanking 120bp 
regions, as evaluated with PMCA (21) (Table S6), sequence-based predicted functional 
significance scores < 0.01, as evaluated with DeepSEA (22) (Table S7), and all four 
SNPs showed remarkably consistent allele-specific chromatin accessibility with the 
Basset model when comparing the experimentally-derived allelic activity in pre-
adipocytes and hypothalamic neurons (Table S8).All 4 SNPs are co-inherited as one 
common haplotype, with each allele in the obesity-risk haplotype associated with 
increased enhancer activity (Fig. 3C), suggesting that they may coordinately regulate 
target gene expression in the same direction (LDhap tool: https:// ldlink.nci.nih.gov). 
Our data suggest that multiple genetic variants in this locus may regulate gene 
expression in both adipose and neuronal tissues. This supports a model in which GWAS 
signals may result from a complex genetic architecture whereby allelic heterogeneity of 
multiple regulatory variants in distinct regulatory elements imparts shared effects 
across tissues, regulating the quantitative and spatial expression of multiple genes (23). 
We next determined the impact of these enhancers on gene expression. Because all four 
regulatory regions with allele-specific enhancer properties map within the 20 kb region 
that we deleted in the mouse genome (fig. S1C), we used mmFtoΔ20 mice to evaluate 
the impact, in vivo, of this deletion on the expression of neighboring genes in adipose 
and brain tissues. We initially assayed the expression of genes in the Fto-Irxb cluster 




WT mice and observed a decreased expression of Irx3 and Irx5 in mmFtoΔ20, but not of 
other genes in the locus (Fig. 4A). The impact of deleting these enhancers on the 
expression of Irx3 and Irx5 was restricted to preadipocytes, with no effect on expression 
in mature adipocytes, as previously described (8). 
We next assayed the impact of the 20 kb deletion on gene expression in mouse 
hypothalamus during embryonic development (E17) as well as in adult mice (10 
weeks). At E17, the 20 kb deletion leads to downregulation of Irx3 and Irx5, with no 
impact on the expression of Fto and Irx6 (Fig. 4B). Similar to adipose, this effect was 
restricted to embryonic development, with no alterations in Irx3 and Irx5 expression in 
adult hypothalami. To further explore the temporally-restricted expression of Irx3 and 
Irx5 in the developing hypothalamus, we assessed single-cell gene expression across 
windows of mouse hypothalamic development in mice (24), and determined that the 
expression of Irx3 and Irx5 is highest at mid-gestation and decreases steadily 
afterwards, being barely detectable in adult neurons (fig. S8). The expression of 
Rpgrip1L was also decreased in hypothalami of mmFtoΔ20 mice (Fig. 4B), raising the 
possibility that regulation of Rpgrip1l in the brain may also contribute to obesity risk, 
as previously suggested (10). 
Our data suggest that variants in multiple enhancers within the FTO obesity-associated 
region regulate the expression of multiple genes in at least two major obesity-relevant 
tissues, adipose and brain, in mice. Next, we tested the impact of the obesity-associated 
region on gene expression in human hypothalamic neuronal precursors. We first 
assayed the dynamic expression of IRX3 and IRX5 during differentiation of human 




correlated and peaks at an early stage of hypothalamic neuronal differentiation, 
decreasing at later developmental stages, paralleling the observations in mice (fig. S9A 
and B). These data further support the possibility that some of the allelic effects of 
obesity-associated SNPs on gene expression may involve developmental phenotypes 
restricted to specific temporal windows and not detected in differentiated, adult tissues. 
A recent report uncovered evidence that the FTO locus variants have effects on BMI in 
early childhood (25), further raising the prospect that the association with BMI may 
involve a combination of developmental and growth phenotypes.   
To test the effect of modulating these enhancers in a model of human hypothalamic 
neurons, we subsequently generated in human iPSCs a genomic deletion of a 36,100 bp 
segment which encompasses the FTO obesity-associated locus and corresponds to the 
deletion engineered in mmFtoΔ20 mice. We differentiated WT and 36,100 bp deletion 
(hsFTOΔ36) iPSCs into hypothalamic arcuate-like neurons (fig. S9C and D) (26–28). 
We performed single cell RNA sequencing (scRNA-seq) in 91,825 cells at the neuron 
progenitor stage to assess transcriptome differences between WT and hsFTOΔ36 cells. 
Single-cell transcriptomic profiling identified distinct cell populations within the 
hypothalamic neuron precursor stage, grouped into distinct subtypes. We defined 
different developmental stages and cell types based on the expression of known 
neuronal markers (29, 30). Cell subtypes were designated as (1) hypothalamic neurons 
at late development time point (Late Dev), (2) hypothalamic neurons at an early 
developmental time point (Early Dev), (3) hypothalamic progenitor cells (HPC), and (4) 
radial glia, together all four subtypes constituting the neurogenic lineage (Fig. 4C and 




assay for alterations in gene expression in cellular sub-groups, we clustered cells based 
on the expression of 8 major neural and hypothalamic markers, including ARNT2, NES, 
NEUROD1, NHLH2, NKX2-1, NPY, OTP and POMC (fig. S10). We found that only in 
cells expressing POMC, which is critical in regulating normal feeding behavior and 
energy homeostasis, the deletion of the 36 kb resulted in reduced expression of IRX3 and 
IRX5 compared to WT cells, supporting our findings in mouse hypothalami (Fig. 4D). No 
other gene in the locus was differentially expressed between the two groups in any other 
cell type cluster. While we performed our analysis in hypothalamic cells, there currently 
is no clear delineation of the precise brain cell populations in which the expression of 
IRX3 and IRX5 is regulated by enhancers and allelic variants within these enhancers in 
the obesity-associated region. Future work tackling this outstanding question will be 
critical to demarcate the molecular, cellular, and organismal phenotypes involved in 
obesity susceptibility in this locus. 
Taken together, our data highlight the complexities that arise during the functional 
dissection of disease-associated loci in humans. Recent work has suggested extensive 
pleiotropy of loci, SNPs, and gene sets underlying associations with polygenic traits in 
humans (4). Also, GTEx has shown that the regulatory effects of eQTLs tend to be highly 
shared across tissues (31). Furthermore, the impact of regulatory variants on molecular 
phenotypes is often dependent on developmental context, with changes in gene 
expression restricted to specific temporal windows (32). Our findings support all these 
observations, demonstrating how the collective effects of regulatory variants are 




phenotypes reminiscent of homeostatic mechanisms governing complex physiological 
traits in vivo, such as body weight regulation.  
There are important limitations to our study. The choice of immortalized cell lines for the 
reporter assays may mask allelic effects of SNPs that would be seen in primary cells. 
Also, the manipulation of candidate genes in mice may result in organismal phenotypes 
that are quantitatively and qualitatively different than the small effect phenotypes elicited 
by allelic variants of SNPs associate with the human trait. Finally, the congruent 
macronutrient preference phenotypes we describe between Irx3-/- mice and humans 
represent but a subset of the feeding behavior phenotypes associated with this locus in 
humans. This may reflect species differences in the function of these genes, but also that 
there are other functions associated with IRX3, IRX5 or other genes in the locus 
(RPGRIP1L or FTO) that contribute to the BMI association in humans. 
Our work suggests that the genetic architecture of a disease-associated locus may include 
allelic heterogeneity, with multiple variants modifying the regulatory properties of 
distinct enhancers with broad tissue-specificity and regulating multiple genes in limited 
temporal windows. These insights provide a mechanistic framework to explain the 
genetic and functional architecture of GWAS loci, predicting that it will often encompass 
multiple phenotypic mechanisms that ultimately converge to modulate disease 
susceptibility. 
Figure legends 
Fig. 1 Regulatory architecture of obesity-associated noncoding elements within 
FTO. (A) PCHi-C interactions emanating from the FTO, IRX3, IRX5, and IRX6 




like neurons (Neurons). The yellow strip highlights the obesity-associated interval. PCHi-
C interactions are presented as gray colored arcs. Red arcs highlight interactions of IRX3 
and IRX5 promoters with obesity-associated region. (B) 1.1 Mb region analyzed by FISH 
in mouse cerebellum encompassing Fto, Irx3, Irx5, and Irx6 genes. Fragment deleted in 
the mmFtoΔ20 mouse is indicated in blue. Fosmids used for analysis in D are indicated 
in red and green. (C) 3D-FISH with Fto, Irx3, Irx5, and Irx6 probes (red) and directly 
distal FTO obesity-associated interval (green), counterstained with DAPI (blue). Bars, 
5m. (D) Box plots represent the distribution of interprobe distances (nm) between 
different probe combinations in Irx3-expressing (cerebellum: cer) and non-expressing 
(cortex: con) brain tissue of mmFtoΔ20 heterozygous mice. Statistical significance of 
differences between data sets was examined using Mann Whitney U tests. n= 50 – 60 WT 
and mmFtoΔ20 alleles each per slide. Abbreviation: FtoLD (FTO obesity-associated 
interval); FtoPr (Fto promoter). 
Fig. 2 Irx3 acts in the brain to regulate metabolism and changes in macronutrient 
selection. (A) Expression analysis of differentially expressed genes between hypothalami 
of Irx3-/- and WT mice using Gene Ontology (GO) annotations. Sankey flow diagram 
showing all genes upregulated in the hypothalami from Irx3-/- animals with high 
enrichment for Cellular Metabolic Processes and the top ranked diseases related to them. 
Gene symbols are shown. (B) Two-bottle choice experiment comparing Irx3-/- and WT 
mice. Data are expressed as mean ± SEM. *, P < 0.05 compared to WT group. (C) A 
regional association plot of the FTO locus. LocusZoom was used to plot the negative 




Fig. 3 Functional variants within the FTO association locus modulate enhancer 
activity in brain and adipose. (A) Functional variants that showed allele-specific 
activity using MPRA (black boxes) and PMAC (red boxes). Colored bars indicate the 
chromatin state annotations from Roadmap Epigenomics Project. Tissues: adipose-
derived mesenchymal stem cell cultured imputed (E025) and adipose nuclei imputed 
(E063); brain hippocampus middle (E071) and fetal brain male (E081). (B) Comparison 
of allele-specific activity of four variants in the FTO obesity-associated interval using 
luciferase reporter assay. The plots show the mean ± SEM from five triplicate 
experiments. *P < 0.05, **P < 0.01, and ***P < 0.001. (C) Segregation of alleles by risk 
or non-risk haplotype and effect on enhancer activity. 
Fig. 4 Evaluation of enhancer activity in the FTO obesity-associated locus in 
neuronal and adipose tissues. Relative expression of Rpgrip1L, Fto, Irx3, Ixr5, and Irx6 
genes in (A) mouse preadipocyte cells, adipose tissue, and (B) hypothalamus. (C) UMAP 
plot showing the different cell populations identified using single cell sequencing. (D) 
Volcano plot of the differential gene expression (DE) analysis between WT and 
hsFTOΔ36 hypothalamic precursor cells with POMC cutoff 95 (counts) and KNN K=11. 
Gray dots represent genes not significantly changed. Green and red dots are genes 
significantly down and up-regulated, respectively. The log fold change (logFC) is shown 
on the x axis and the negative log10 of the adjusted P value is shown on the y axis 
(logFC cutoff > 0.6 or < -0.6, and adjusted P value < 0.05 as significantly differentially 
expressed). IRX3 and IRX5 are significantly differentially expressed across two 
conditions with KNN K ranging from 10 to 13 (IRX3), from 11 to 13 (IRX5), and cutoff 




cells); Early Dev (hypothalamic neurons at early development time point); Late Dev 
(hypothalamic neurons at late development time point). For qPCR analysis error bars 
represent the mean ±SEM. *P < 0.05 and **P < 0.01 compared to WT. 
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Materials and Methods 
Mice 
All mice (C57BL/6J) originally were obtained from Charles River Laboratories, Inc. 
(Wilmington, Massachusetts, USA). The Irx3-/-, Irx5-/-, Irx6-/-, and mmFtoΔ20 
knockout mice were generated using Crispr/Cas9 genome editing. Male mice were 
weaned at 4 weeks of age, and weekly records of weight were maintained throughout the 
study. Weaned mice were housed up to five per cage. For diet-induced obesity studies, 
10-week-old male mice were subjected to 55% high-fat diet (HFD) (Harlan Teklad, Cat 
No. TD.93075) for 10 weeks. Body weight was measured every week from 4 to 20 weeks 
of age, and Dual-Energy X-ray Absorptiometry (DEXA) scans were preformed using a 
Lunar PIXImus II (GE Medical Systems) in order to analyze the animals body 
composition: body length (cm), bone mineral density (BMD, g/cm2), body fat mass (%). 
Prior to scanning, animals were anesthetized with ketamine, and their body length was 
determined. Mice were housed on a 12-hour light/dark cycle with ad libitum access to 
food and water according to their assigned diet. Normal Diet (ND) groups received 14% 
fat, 64.8% carbohydrate, and 21.2% protein mouse chow (Harlan Teklad, Cat No. 
2920X). High-fat diet (HFD) groups received 55% fat, 25.5% carbohydrate, and 16.4% 
protein mouse chow (Harlan Teklad, Cat No. TD.93075). All procedures were conducted 
with approval of the Institutional Animal Care and Use Committee (IACUC) of 
University of Chicago (ACUP-71656; IBC0934). 
 
Generation of knockout animals 
Irx3-/-, Irx5-/-, Irx6-/-, and mmFtoΔ20 knockout mice were generated using 
CRISPR/Cas9 genome editing. The sgRNAs used to target Irx3, Irx5, Irx6, and Fto were 
described in Table S10. 
 
Genotyping 
The genotypes of mutant mice were determined by PCR amplification of genomic 
DNA extracted from tails. PCR was performed for 30 cycles at 95 °C for 30 sec, 60 °C 
for 30 sec, and 72 °C for 1 min, with a final extension at 72 °C for 5 min. PCR 
amplification was performed using the primer sets in Table S10 and the PCR products 
were size-separated by electrophoresis on a 4% agarose gel for 1 h. 
 
In vivo glucose tolerance test 
Starting at 10 weeks of age, Irx3-/-, Irx5+/-, Irx6-/-, and WT littermates were fed a 
high fat diet (55% fat, Harlan Teklad) for 10 weeks. After this 10-week period, the 
animals were tested for glucose sensitivity by intraperitoneal glucose tolerance test 
(IPGTT). Prior to IPGTT, mice were fasted for 4h and an initial blood glucose reading 
was taken. This fast was followed by intraperitoneal injection of 2 mg/kg dextrose 
(Millipore Sigma, CAS 50-99-7), and subsequent blood glucose checks using an 
AccuChek Aviva glucometer. Blood glucose readings were taken at 15, 30, 60, and 120 
min after dextrose injection and the area under curve (AUC) describing blood glucose 
levels during IPGTT was calculated by trapezoidal rule by using the following equation: 
AUC = 0.25×(fasting value) + 0.5×(half-hour value) + 0.75×(1-hour value) + 0.5×(2-hour 





Real time qPCR 
Total RNA was isolated from preadipocytes isolated from the inguinal white fat pad 
(iWAT) using the RNA extraction reagent RNeasy Mini Kit (Qiagen, Cat No. 74104). 
cDNA synthesis was performed using SuperScript III First-Strand Synthesis System 
(Thermo Fisher Scientific, Cat No. 18080-044). Real time qPCR reactions were 
performed by using SsoAdvanced Universal SYBR Green Supermix (Bio-Rad 
Laboratories, Cat No. 1725270). Real time qPCR conditions were: 95 °C for 15 min 
followed by 40 cycles of 15 sec at 95 °C, 30 sec at 56 °C, and 30 sec at 72 °C. Relative 
gene expression was determined using Hprt expression as an endogenous internal control. 
All real time RT-qPCR primers were purchased from Bio-Rad Laboratories: Irx3 
(qMmuCED0040332), Irx5 (qMmuCID0009561), Irx6 (qMmuCED0003544), Adrb3 
(qMmuCED0001037), Cidea (qMmuCID0007140), Prdm16 (qMmuCID0010482), and 
Hprt (qMmuCID0005679). 
 
Two-bottle choice experiment  
The two-bottle tastant experiment was performed as previously described (17). For the 
two-bottle choice studies, 10-week-old male mice (wild-type and Irx3-/- animals) were 
individually caged. Mice were given ad libitum access to one bottle with water and one 
bottle of a test solution for 3 days. All solutions were prepared with deionized water and 
served at room temperature. The test solution contained one of the following: 10% 
sucrose (Millipore Sigma, CAS 57-50-1), 10% casein (CAS 9000-71-9), 20% intralipid 
(Baxter, Cat No. 2B6061), or 10 mM sucralose (Millipore Sigma, CAS 56038-13-2). The 
spillage from drinking tubes was estimated daily by recording the change in fluid levels 
of two drinking tubes that were placed on an empty cage, where one tube contained that 
day’s test solution and the other tube contained water. 
 
Statistical analysis 
The results for real time qPCR, in vivo glucose tolerance test, body weight and 
composition (body length, bone mineral density and body fat mass), luciferase assay and 
two-bottle choice experiments are shown as mean ± SEM. Statistical significance of 




SGBS (Simpson–Golabi–Behmel Syndrome) preadipocytes were kindly donated by 
Martin Wabitsch (Ulm University Medical Center, Ulm, Germany). SGBS cell growth 
was performed as previously described by Wabitsch et al. (33) and Fischer-Posovszky et 
al. (34). The SGBS cell line was cultured in DMEM/Ham’s F12 (1:1) medium (Thermo 
Fisher Scientific, Cat No. 31330-038) supplemented with 10% FCS (Thermo Fisher 
Scientific, Cat No. 10270-106), 17 μM biotin (Millipore Sigma, Cat No. B-4639), 33 μM 
pantothenic acid (Millipore Sigma, Cat No. P-5155), and 1% penicillin/streptomycin 
(Thermo Fisher Scientific, Cat No. 15140-122). We maintained cells at 37 °C and 5% 
CO2.  Murine HT22 hippocampal neuronal cell line was a gift from David Schubert (The 
Salk Institute, California, USA) (35). These cells were maintained in Dulbecco‘s 
modified Eagle’s medium (DMEM) (Thermo Fisher Scientific, Cat No. 11995) 




(36). Murine 3T3-L1 preadipocyte subline (derived from 3T3 fibroblasts of albino Swiss 
mouse embryo) was purchased from ATCC (3T3-L1, ATCC CL-173). The cells were 
cultured in growth medium composed of DMEM high glucose (ATCC, Cat No. 30-2002) 
supplemented with 10% bovine calf serum (ATCC, Cat No. 30-2030), and 1% 
penicillin/streptomycin (Thermo Fisher Scientific, Cat No. 15140-122), at 37 °C in 5% 
CO2. Human iPSCs (hiPSCs) (37) were grown in Essential 8 (E8) Medium (Thermo 
Fisher Scientific, Cat No. A1517001) supplemented with 1X penicillin-streptomycin 
(Corning, Cat No. 30002C1) on Matrigel-coated tissue culture dishes (Corning, Cat No. 
354230). Cells were passaged when they were ~65% confluent using enzyme-free 
dissociation solution (30 mM NaCl, 0.5 mM EDTA, 1X PBS minus magnesium and 
calcium) and maintained in E8 Medium with 10 μM Y-27632 dihydrochloride (Abcam, 
Cat No. ab120129) for 24 hr. Medium was replaced daily. All cell cultures routinely 
tested negative for mycoplasma contamination using the Universal Mycoplasma 
Detection Kit (ATCC, Cat No. 30-1012K). 
 
Hypothalamic neuron differentiation 
hiPSCs were differentiated into hypothalamic arcuate-like neurons, as previously 
described by Wang et al. (28). Briefly, the sonic hedgehog (SHH) (R&D Systems, Cat. 
No. 1845‐SH) signaling pathway was activated and transforming growth factor β (TGFβ) 
and bone morphogenetic protein (BMP) signaling were inhibited, followed by inhibition 
of NOTCH pathway, leading to neuronal differentiation, ventralization, and hypothalamic 
differentiation. After differentiation Brain-derived neurotrophic factor (R&D Bioscience, 
Cat No. 248‐BD) was introduced to promote neuronal maturation of pro-
opiomelanocortin (POMC) and Neuropeptide Y (NPY) neurons. Cells were collected at 
different time points and processed for in situ promoter capture HiC (PCHi-C), total RNA 
extraction, and single cell RNA-seq. 
 
RNP-mediated CRISPR/Cas9 editing of hiPSCs 
The hsFTOΔ36 knockout hiPSC line was generated using the ribonucleoprotein 
(RNP) genome editing machinery purchased from Integrated DNA Technologies (IDT). 
The RNA oligos (crRNA) used to target the human obesity association region in the first 
intron of the FTO gene are described in Table S10. The RNA oligos were designed using 
IDT software and two RNA oligos were designed in order to delete the human obesity 
association region in the first intron of the FTO gene (36,100 bp). The crRNA and 
tracrRNA were complexed according to manufacturer’s instructions. Briefly, the crRNA 
and tracrRNA were mixed in equimolar concentrations (50 μM of each), then incubated 
at room temperature for 20 minutes to form the ribonucleoprotein. The crRNA (1) and (2) 
were annealed with tracrRNA in individual reactions. The two RNP complexes were 
nucleofected into human iPSC cells using Amaxa 2b-Nucleofector device (Bioscience 
Lonza) with the program A23. Cells were plated into one 22 cm2 flask. Single cell 
colonies were picked and screened for the presence of homozygous deletion bands using 
PCR. The PCR reaction was performed for 30 cycles at 95 °C for 30 sec, 60 °C for 30 
sec, and 72 °C for 1 min, with a final extension at 72 °C for 5 min. PCR amplification 
was performed using primer set in Table S10 and PCR products were size-separated by 





Construction of luciferase reporter assay vectors 
We evaluated the enhancer activity of all the variants identified by MPRA in the 
FTO obesity-associated locus (Table S3). We synthesized 1 kb long fragments (+/-500 bp 
window centered on both variants, risk and non-risk) (gBlocks Gene Fragments, IDT). 
Both alleles (risk and non-risk) for each variant were inserted into the multiple cloning 
site upstream of the minimum promoter of the pGL4.23[luc2/minP] vector (Promega) and 
tested by luciferase reporter assay. We verified the identity of each construct clone by 
DNA sequencing. The assay was run in triplicates, and all constructs were transfected 
into mouse hippocampus (HT22) cell line and mouse preadipocyte (3T3-L1) cells. As a 
negative control (scramble), we used a DNA sequence (chr9:6,161,550-6,162,024) 
devoid of any epigenetic marks of active chromatin. 
 
Luciferase assay 
Luciferase assays were conducted in 24-well plates. Transfection with 500 ng 
construct DNA using Lipofectamine LTX with Plus Reagent (Thermo Fisher Scientific, 
Cat No. 15338030) was performed in triplicate. HT22 (24-well plate) were transfected 
one day after plating at approximately 80% confluence and 3T3-L1 (24-well plate) three 
days after plating at approximately 70% confluence. Both cell lines were co-transfected 
with the firefly luciferase constructs with the Renilla luciferase reporter vector 
pGL4.73[hRluc/SV40] to normalize the transfection efficiency. Twenty-four hours after 
transfection, cells were washed with PBS and lysed in 1x passive lysis buffer (Promega, 
Cat No. E1910) on a rocking platform for 30 min at room temperature. The luciferase 
assays used for allele specific enhancer activities had between 4 technical replicates per 
construct, where different DNA preps were used and the cells were transfected, collected, 
and analyzed on different days. 
 
Massively Parallel Reporter Assay (MPRA) 
Of the 97 lead-SNPs identified by the GIANT consortium (19), one (rs1558902) 
resides in the FTO obesity-associated intronic region. Using the 1000 genomes Phase 3 
database in European individuals (CEU), we identified a total of 87 biallelic SNPs in 
strong Linkage disequilibrium (LD) (r2 >0.8) with the rs1558902 variant in a 100 kb 
interval (+/- 50 kb window centered on rs1558902) that have a minor allele frequency 
(MAF) > 5% to test with MPRA. The MPRA library was generated as described by 
Melnikov et al. (38) with modifications described below. Each fragment was designed as 
such: 5 -ACTGGCCGCTTCACTG-enh-GGTACCTCTAGA-barcode-
AGATCGGAAGAGCGTCG-3. DNA enh fragments were synthesized using an Agilent 
array at 230 bp lengths (Agilent Technologies). Each allele of the 87 variants was 
synthesized with 175 base pairs of human DNA context. Each allele was assigned 18-19 
unique 10 bp DNA barcodes that were generated using a randomized set of base-
composition matched A, C, T, or Gs. Upon receipt from Agilent array, the fragment pool 
was resuspended in 100 µl of nuclease-free water and Gibson Assembly homology arms 
were added via PCR using a Micellula DNA emulsion and Purification Kit (EURx 
Molecular Biology Product, Cat No. E3600-01). Using Gibson Assembly (New England 
Biolabs, Cat No. E2611S), these fragments were then ligated into the pMPRA1 vector 
(Addgene #49349). After assembling this vector, a truncated eGFP (60 bp long) 




between the enh fragments and barcodes using T4 DNA ligase (New England Biolabs, 
Cat No. M0202S) at 16ºC for 12 hr. To preserve library complexity, the efficiency of 
cloning transformations was maintained at >108 cfu/μg. The resulting plasmid library was 
transfected into at least 10 million hippocampus (HT22) or preadipocyte (3T3-L1) cells 
per experimental replicate. After transfection, mRNA was extracted from total RNA 
using Invitrogen Dynabeads (Thermo Fisher Scientific, Cat no. 61001) and treated with 
Promega RQ1 DNAse (Promega, Cat No. M6101). First-strand cDNA was synthesized 
from 1 μg mRNA using Superscript III Reverse Transcriptase (Thermo Fisher Scientific, 
Cat No. 18080-044). cDNA was treated with RNAse A (Thermo Fisher Scientific, Cat 
No. 12091-021) and RNAse T1 (Thermo Fisher Scientific, Cat No. EN0541) for one hour 
and then cleaned with the Qiagen Minelute PCR purification kit (Qiagen, Cat No. 28004). 
MPRA sequencing libraries were generated directly from the total amount of cDNA 
reaction. The libraries were sequenced in indexed pools using 50-nt paired-end reads on 
Illumina HiSeq 4000 instruments (Illumina).  
 
MPRA data analysis 
Barcode sequences were retained if they were exact matches to synthesized 
barcodes. Each barcode was then counted and barcodes with low expression were 
removed from analysis. Enhancer activity per barcode was calculated using the following 
equation: log2 (output(CPM) – input(CPM)). Activity was quantile normalized and a 
one-tailed Mann-Whitney U Test with FDR (<5%) was used to assess enhancer 
significance for all alleles retaining at least 7 unique barcodes. For regions where one or 
both alleles were considered enhancers, we then performed a two-sided Mann-Whitney U 
test with FDR (<5%) to determine significance of differences between alleles. MPRA 
experiments were comprised of two soft biological replicates with 2 technical replicates 
per soft biological replicate. A replicate was considered “biological” if the input DNA 
library was separately cloned from the beginning from our Agilent oligonucleotides. 
 
Phylogenetic Module Complexity Analysis (PMCA).  
We used the PMCA method described in (21) with several modifications. Briefly, 
972 position weight matrices from the Catalog of Inferred Sequences of Binding 
Preferences (the Catalog of Inferred Sequences of Binding Preferences (CIS-BP)) were 
grouped in 192 motif matrix families using TomTom, as previously described (39), and 
families were further overlapped by motif name to create a many-to-many mapping 
where individual TFs had multiple motifs annotated. MOODS (40) was used to scan a 
variant-flanking regions of the human reference genome (variant at mid-position) and its 
orthologous regions for cross-species conserved groups of transcription factor binding 
site motifs, so called groups of transcription factor binding site motifs, so called motif 
modules. A module is defined as a set of binding site motifs, whose order and distance 
range is conserved across species (21). The PMCA method counts instances of conserved 
motifs within conserved modules within the 120bp sequence context of a given variant. 
Enrichments of motifs in conserved modules are computed 10,000 permutations of 
orthologous sets. The PMCA method counts instances of conserved motifs within 
conserved modules within the 120bp sequence context of a given variant. Enrichments of 





Basset convolutional neural network (CNN)  
ATAC-seq IDR reproducible peaks of iPSC derived neuron differentiation along 
with day 0, day 3, day 6, and day 14 of differentiation of immortalized AMSCs (dbGAP, 
PRJNA664585) (20), were collated and normalized to 60bp along with 163 other cell 
types (41). A Basset model was trained with three convolutional layers (256, 128, and 
128 filters; 9, 7, and 5 filter sizes; 0.1 dropout, 2 width pooling) and three fully connected 
hidden layers with 128 units and 0.25 dropout, using weight normalization 5, a learning 
rate of 0.01, and momentum of 0.995. The best validation accuracy model was used for 
downstream analysis (20). 
 
DeepSEA 
SNPs in high LD (r^2 > 0.8 in 1000G EUR) with the lead variant were formatted as 
a VCF file and evaluated for activity using the original DeepSEA model 
(http://deepsea.princeton.edu/) (22). Functional significance scores were extracted as 
described, reproduced here: "the DeepSEA functional significance score for a variant is 
defined as the product of the geometric mean E value for predicted chromatin effects and 
the geometric mean E value for evolutionary conservation features" (22). 
 
RNA-sequencing 
Total RNA from adult mouse hypothalamus was extracted using Trizol (Millipore 
Sigma, Cat No. 15596018). Quality and quantity of RNA samples were measured using 
Agilent 2100 Bioanalyzer instrument (Agilent). RNA-seq libraries were generated using 
the TruSeq RNA Library Prep Kit v2 (Illumina, Cat No. RS-122-2001) and were 
sequenced on Illumina HiSeq 2500 platform (Illumina). Reads were aligned to mm9 with 
STAR 2.5.1b [PMID: 23104886] without FilterMultimapNmax 1 and exon models from 
the basic set of Gencode release M1 (sjdbGTFtagExonParentTranscript). Read counts per 
gene were obtained by assigning reads to exons based on their alignment coordinates. We 
used limma 3.26.8 [PMID: 25605792] with voom transformation of read counts and 
quantile normalization to identify differentially expressed genes with a minimum 
absolute fold-difference of 1.5 and adjusted P value of 0.05. No correction for batch 
effects was applied because samples clustered in control/treatment groups as expected. 
The human Gene Ontology (GO) associations of GO terms [PMID: 10802651] to genes 
and the GO database were downloaded on January 22, 2016 from 
http://geneontology.org/gene-associations and terms and parent terms were assigned to 
Gencode mouse M1 genes. A hypergeometric test was used to calculate the statistical 
significance of the difference of the number of genes associated with a given GO term in 
a particular gene set and the universe of all genes (P < 0.05). P values were corrected 
with the R package p.adjust function using the fdr method. Five biological replicates 
were performed. 
 
In situ promoter capture Hi-C (PCHi-C) 
Five million human SGBS adipocytes and hypothalamic arcuate-like neurons from 
iPSCs were harvested from tissue culture dishes and resuspended in formaldehyde 
solution, 37% (Millipore Sigma, Cat No. 104003) to a final concentration of 1%, v/v for 
10 minutes at room temperature. Glycine (Millipore Sigma, CAS 56406) was added to a 




stored at −80 °C. The in situ PCHi-C libraries were performed as in Montefiore et al. 
(42).  
 
In situ PCHi-C analysis 
SGBS: paired-end reads were separately aligned to hg19 with Bowtie 2 version 
2.3.4.1. Aligned reads were then paired and Hi-C interactions were called with HOMER 
4.9 (PMID: 20513432) with the program findHiCInteractionsByChr.pl and parameters -
res 2000 -superRes 5000. 
Hypothalamic arcuate-like neurons: HiCUP (version 0.5.9) was used to map PCHi-C 
reads to the genome and remove technical artifacts. To improve processing speed, raw 
fastqs were divided into 15 segments. Mapping, artifact detection, and deduplication was 
performed on each segment independently. Resulting bam files were then merged and 
HiCUP de-duplication was re-performed on the merged sample to remove PCR artifacts. 
CHiCAGO (version 1.14.0) was performed to identify significant (-log (weighted P 
value) >5) promoter-baited interactions, using a convolution background model and P 
value weighting to account for distance-dependent random interactions between genomic 
location and technical artifacts. CHiCAGO was performed independently on each 
replicate and on the merged set of all two replicates from each time point to identify 
significant chromatin interactions specific to that time point. Significance was defined as 
a CHiCAGO score > 5. To identify both significant interactions and interactions which 
do not meet CHiCAGO’s significance threshold, CHiCAGO was run once to identify 
only significant interactions and a second time with no threshold to report all promoter-
baited interactions.  
Two technical replicates for each cell line were performed derived. Each technical 
replicate was analyzed alone, and additionally the technical replicate raw sequencing data 
was merged and analyzed to produce merged datasets. Merged datasets and individual 
replicate datasets were used in downstream analyses. 
 
Fluorescence in situ hybridization (FISH) 
Whole mount mouse brains were fixed in 4% paraformaldehyde (PFA) overnight at 
4 ºC (Millipore Sigma, Cat No. P6148). The PFA-fixed brains were permeabilized in 
0.5% Triton X-100 (Millipore Sigma, Cat. No. 648463), washed in PBS, and stored at 
−80 °C. 3D-FISH was carried out as previously described (43). Fosmid clones were 
prepared and labelled as previously described (44). Between 160 and 240 ng of biotin- 
and digoxigenin-labeled fosmid probes were used per slide, with 16-24 g of mouse Cot1 
DNA (ThermoFisher, Cat No. 18440016) and 10 g salmon sperm DNA. For 4-color 
FISH, similar quantities of the additional fosmid were labeled with Green496-dUTP 
(Enzo Life Sciences, Cat No. ENZ-42831). Fosmid clones used as FISH probes are listed 
in Table S11 and genome co-ordinates were taken from the USCS mouse genome 
browser (NCBI37/mm9). 
 
Image analysis of FISH 
Slides were imaged using a Photometrics Coolsnap HQ2 CCD camera and a Zeiss 
AxioImager A1 fluorescence microscope with a Plan Apochromat 100x 1.4NA objective, 
a Nikon Intensilight Mercury based light source (Nikon UK Ltd.), and either Chroma 




Technology Corp.) with the excitation and emission filters installed in Prior motorized 
filter wheels. A piezoelectrically driven objective mount (PIFOC model P-721, Physik 
Instrumente GmbH & Co.) was used to control movement in the z dimension. Step size 
for z stacks was set at 0.2 µm. Hardware control, image capture, and analysis were 
performed using Nikon Nis-Elements software (Nikon UK Ltd.). Images were 
deconvolved using a calculated point spread function with the constrained iterative 
algorithm of Volocity (PerkinElmer Inc.). Image analysis was carried out using the 
Quantitation module of Volocity (PerkinElmer Inc.). 
 
GWAS sweet versus salty 
GWAS summary statistics for sweet versus salty preference were obtained from 
23andMe based on 118,950 participants' answers to the question "When you’re in the 
mood for a snack, what kind of snack do you usually reach for?”. Participants could 
choose one of four responses (Sweet / Salty or savory / Both / Neither), and only those 
that responded "Sweet" or "Salty or savory" were included. The results are visualized in a 
regional association plot generated by LocusZoom (45) centered on rs1421085, at the 
FTO locus. The negative log10 of the P value of all genotyped SNPs in the region was 
plotted on the y-axis and the color of each SNP represents the pairwise linkage 
disequilibrium (LD) of that SNP with rs1421085. LD estimates were generated based on 
the 1000 Genomes Project EUR population. The GWAS was conducted by 23andMe 
Personal Genome Service and the single-phenotype GWAS were run as previously 
showed by Hinds et al. (46). Research participants’ answers to the questionnaire were 
assessed. A total of 54,901 participants (46%) answered “Sweet” and 64,049 participants 
(54%) answered “Salty or savory.” Participants who answered “Both” or “Neither” were 
excluded. Twenty-nine genomic loci were identified that passed criteria for genome-wide 
association significance (summarized in Table S12). 
 
4C-sequencing 
4C-seq was performed as previously described (47). In brief, single cells from three 
whole mouse hypothalami were crosslinked in 2% formaldehyde-PBS-10% FCS for 30 
min at room temperature. After crosslinking, cells were incubated in lysis buffer for one 
hour, washed in 1X PBS, and resuspended in the correct enzyme buffer. SDS (to a 
concentration of 0.3%), Triton X-100 (to a concentration of 2.6%), and 200 units of the 
first enzyme were added for a 12 hours incubation in a thermomixer at 37 °C and 900 
rpm; The enzyme were heat-inactivated and first ligation was performed, adding 50 units 
of ligase to a volume of 7 mL and then incubating overnight at 16 °C. After first ligation, 
50 units of the second enzyme were added and cells were incubated for 4 hours in a 
thermomixer at 37 °C and 900 rpm, followed by heat inactivation of the enzyme (65 °C 
for 25 min). Samples were diluted with ligation buffer to a DNA concentration of < 5 
ng/μl. 100 units of ligase was then added for overnight incubation at 16 °C. DNA was 
purified using Qiagen PCR purification kit (Qiagen, Cat No. 28104) in 10 mM Tris pH 
7.5. The primers and enzymes information are in Table S10. Primers were extended with 







In silico analysis of deposited scRNA-seq data 
Single cell RNA-seq data from Romanov et al. (24) were downloaded from the 
NCBI Gene Expression Omnibus (GEO accession #: GSE132730), loaded into the R 
package Seurat (v3.1), and filtered using default parameters. Gene expression in each cell 
type at different mouse development stages (E17, P0, P2, P10, and P23) was normalized 
using the NormalizeData function and the expression of each gene was scaled using the 
ScaleData function. Only neurons which expressed Irx3 and Irx5 were subclustered. Irx3 
and Irx5 expression was determined by identifying highly variable genes and was used as 
an input for dimensionality reduction via principal component analysis (PCA). The 
identified principal components were then used as an input for clustering analysis using 
the FindClusters function. 
5-prime single-cell RNA library construction and sequencing  
Cells were processed and all steps were performed following the 10X standard 
manufacturer’s protocols. We used the Chromium Single Cell 5′ Library & Gel Bead Kit 
v2 (10X Genomics, Cat No. PN-1000020). Four technical replicates were run in parallel 
for each sample (hypothalamic progenitor cells WT and hsFTOΔ36). In brief, between 
8000 and 10000 cells were recovered for library preparation and sequencing. All samples 
and reagents were prepared and loaded into the chip. Then, the Chromium Controller was 
run for droplet generation. Reverse transcription was conducted in the droplets. cDNA 
was recovered through demulsification and bead purification. Pre-amplified cDNA was 
further subjected to library preparation. Libraries were sequenced on an Illumina Hiseq 
4000. 
 
Single-cell RNA-seq data processing 
Pre-processing: Raw sequencing data from each sample were aligned to the human 
reference genome (hg38) (48) and the GencodeV27 gene annotation (49) using 
STARsolo v2.7.3 (50) with default settings for 10x scRNA-seq data. Read counts were 
obtained for each cell barcode and annotated gene in the reference. The appropriate cell 
barcode file (737K-august-2016.txt) was obtained from: 
https://github.com/10XGenomics/cellranger/tree/master/lib/python/cellranger/barcodes. 
The raw matrices were used for all downstream analyses. We applied the following pre-
processing procedures on the UMI counts matrix: we first filtered out cells that expressed 
fewer than 3 different genes, and then filtered out genes expressed in fewer than 500 
cells. There were eight replicates in total done at two different times (first two replicates 
and then six replicates), four replicates for each of the two conditions (hypothalamic 
progenitor cells WT and hsFTOΔ36). After the pre-processing procedures, the numbers 
of retaining cells and genes as well as mitochondrial gene content (using a threshold of 
20%) for each replicate are included in the Table S13. 
Differential Expression Analysis: Merging K Nearest Neighbors to Meta Cells: Only 
12.04% of all entries in the UMI count matrix (eight replicates combined together) are 
non-zero values. For the non-zero entries, most have a UMI count of 1. Only 4.98% of 
entries contain UMI counts equal to or greater than 2. To enhance signals in the sparse 
UMI count matrix obtained from scRNAseq, we used K nearest neighbor (KNN) (51) 
smoothing to aggregate gene-level UMI counts and form meta-cells. This was done in 
each replicate individually. The KNN algorithm adopts a step-wise approach, whereby 




larger set of nearest neighbors was identified for each cell based on those minimally 
smoothed profiles, and the raw data were then smoothed using these larger sets of 
neighbors. Additional steps using increasing ki were performed until the desired degree 
of smoothing is reached. We used a series of K values for ranging from 8 to 13. The 
choices of K were heuristic. We ruled out K values smaller than 8 because such Ks did 
not effectively enhance the signals. We ruled out K values larger than 13 because such Ks 
could introduce false positives. After forming the meta-cells for each replicate, we 
combined all the meta-cells from the eight replicates together, and then checked 
differential expression across the two conditions.  
Identifying cells with high expression of POMC: Because cells collected in this 
study were not fully differentiated hypothalamic neurons, we expected that a very small 
fraction of cells would highly express POMC. We tried fairly high cutoffs, where we 
selected the top 7.2% to 1.6% of POMC-enriched-cells based on the rankings of POMC 
expression. The numbers of cells across the two conditions, and the mitochondrial 
content after KNN and identification of cells with high expression of POMC can be 
found in the Table S14.  
DE analysis: Log transformation of normalized data can introduce spurious 
differential expression effects into scRNA-seq data (52). This effect is particularly 
pronounced when normalization size factor distributions differ strongly between tested 
groups. Therefore we focused on DE analysis tools which work with counts data. A 
comparison study of DE analysis suggested that edgeR is among the best performing DE 
analysis tools for scRNA-seq data (53). We thus used edgeR (54) to analyze the 
aggregated meta-cells for differential expression between WT and hsFTOΔ36 
hypothalamic progenitor cells. The analysis pipeline used in this paper was obtained from 
(55). Using a cutoff value of -0.6 for log fold change and a cutoff of 0.05 for adjusted P 
value, we found no evidence for differential expression of RPGRIP1L between WT and 
hsFTOΔ36 cells, regardless of the choice of K and the cutoffs for POMC expression. 
There was no evidence for differential expression of FTO between the two conditions 
either, regardless of the parameter choices. For both IRX3 and IRX5, with K = 8 and 9, 
they were not differentially expressed between the two conditions for all POMC cutoffs. 
However, as we increased the POMC cutoff with those two Ks, IRX3 and IRX5  were 
more likely to be differentially expressed between WT and hsFTOΔ36 cells. With K = 
10, 11, 12, and 13, for low POMC cutoffs, IRX3 and IRX5 were not differentially 
expressed between the two conditions. As we gradually increased the POMC cutoff, IRX3 
and IRX5 were differentially expressed, with their expression being reduced in 
hsFTOΔ36 compared to WT cells. The logFC and P values corresponding to different 
cutoffs and different Ks are in Table S15. We also checked the following hypothalamic 
and neuronal markers: ARNT2, NES, NEUROD1, NHLH2, NKX2-1, NPY, OTP, and 
focused on cells with enriched expression of these genes, but we did not detect 
differential expression of IRX3 and IRX5 between the two conditions. We listed the 
numbers of cells in each of the two conditions and the mitochondrial content after KNN 
and identification of enriched cells in Table S16. We also listed the logFC and P values 








Fig. S1. Regulatory architecture of obesity-associated noncoding elements within 
FTO. (A) 4C-seq profiles of Fto, Irx3, Irx5, and Irx6 gene promoters in adult mouse 
whole hypothalamus. Spider plots show statistically significant contacts (blue arcs) of 
each viewpoint. The obesity-associated interval is highlighted in red. (B) Evolutionary 
conservation in the obesity-associated locus within FTO (chr16:53731249–54975288), 
among different species (7). (C) Overview of the CRISPR/Cas9 strategy to delete 20,204 
bp within the first intron of the Fto gene. The gRNA-targeting sequence (gRNA) is 
underlined and the PAM sequences are indicated in bold. Exons are represented as thick 
blue boxes, introns are indicated as blue lines with arrows, and the red boxes indicate the 
two DNA-targeting regions. Agarose gel shows the screening of F0 mouse tail genomic 
DNA. PCR analysis of the targeted locus showed a 265 bp band corresponding to the 





Fig. S2. Chromatin conformation of  obesity-associated noncoding region within 
FTO. (A) Capture Hi-C interactions emanating from the obesity-associated interval 
within FTO gene in primary human preadipocytes (GEO:GSE140782) (12). The yellow 
strip highlights the obesity-associated interval. The capture Hi-C interactions are 
presented as gray colored arcs. Red arcs highlight interactions of obesity-associated 
region with IRX3 and IRX5 promoters. (B) Representative image of dapi-stained tissue 
sections derived from lung. Bars 6 m. (C) Box plots represent the distribution of 
interprobe distances (nm) between different probe combinations between WT and 







Fig. S3. Generation of Irx3, Irx5, and Irx6 mutant mice using CRISPR/Cas9 editing. 
(A) Irx3. (B) Irx5. (C) Irx6. The gRNA-targeting sequence (gRNA) is underlined, and the 
PAM sequences are indicated in bold. Exons are represented as thick blue boxes, introns 
are indicated as blue lines with arrows, and the yellow boxes indicate the DNA-targeting 
region. Red hexagons indicate a stop codon generating a truncated protein. Agarose gel 
showing the PCR products generated from DNA containing successfully targeted Irx3, 
Irx5, or Irx6 from F0 mouse tail genomic DNA. The DNA sequence from WT animals 





Fig. S4. Irx3-/- and Irx5+/- knockout mice are lean and protected against diet-
induced obesity. (A, D, G) Representative photograph (left panel) and anatomic view 
(right panel) of wild-type (WT) and Irx3-/-, Irx5+/-, and Irx6-/- mice after 10 weeks of 
being fed a high-fat diet (HFD). Yellow dotted lines show perigonadal white adipose 
tissue (PWAT). (B, E, H) Body weight gain in mice fed a normal diet (ND) and after 
HFD in Irx3-/-, Irx5+/-, and Irx6-/-, respectively. (C, F, I) Relative gene expression in 
PWAT after HFD comparing WT animals and Irx3-/-, Irx5+/-, and Irx6-/-. Statistical 
significance was determined by Student t test. Data are expressed as mean ± SEM. *P < 





Fig. S5. Effects of a high-fat diet on glucose tolerance, body length, fat mass and 
bone density. (A, B, C) Intraperitoneal glucose tolerance test (IPGTT) in WT and Irx3-/-
, Irx5+/-, and Irx6-/- mice, respectively. (D, H, L) Graphs show the area under the curve 
(AUC) of the blood glucose concentration levels measured during IPGTT of WT and 
Irx3-/-, Irx5+/-, and Irx6-/-, respectively. (E, I, M) Body fat mass ratio as a percentage of 
body weight after HFD for 10 weeks, Irx3-/-, Irx5+/-, and Irx6-/-, respectively. (F, J, N) 
Body length after HFD for 10 weeks, Irx3-/-, Irx5+/-, and Irx6-/-, respectively. (G, K, O) 
Bone mineral density (BMD) after HFD for 10 weeks, Irx3-/-, Irx5+/-, and Irx6-/-, 
respectively. Statistical significance was determined by Student t test. Data are expressed 





Fig. S6. Expression analysis of Irx3-/- hypothalamus and changes in macronutrient 
selection. (A) RNA-seq transcriptional profiling of differential gene expression (DE) 
between Irx3-/- and WT hypothalamus using Gene Ontology (GO). Pie chart shows the 
distribution of all upregulated biological process in Irx3-/- hypothalamus. Numbers 
indicate the percentages of genes in each GO category. (B) Sankey flow diagram showing 
all genes upregulated in the hypothalami from Irx3-/- animals with high enrichment for 
regulation of hormone levels and the top ranked diseases related to them. Gene symbols 
are shown. (C) Intake of Casein, Intralipid, or Sucralose in WT and Irx3-/- mice. Data are 





Fig. S7. Several variants within the first intron of FTO exhibit allele-specific 
enhancer activities. (A) The genomic landscape of the FTO GWAS association locus. 
Promoter capture Hi-C interactions from SGBS preadipocytes are shown as arcs that 
originate from the promoter of IRX3 (dark blue), IRX5 (light blue), IRX6 (purple), and 
FTO/RPGRIP1L (yellow). The location of the GWAS lead variant (rs1558902) in the 
first intron of FTO is indicated with an arrow. Variants tested with MPRA  mapping 
within enhancers are shown directly above the arrow as purple, gray, or green colored 
lines (variants tested by MPRA). Gray variants were significant in both cell types, green 
were significant in HT22, and purple were significant in 3T3-L1. Variants with allele-




activity levels for all constructs tested with MPRA, along with a Venn diagram showing 
the number of enhancers found in each cell type. (C) MPRA activity measures for each 
FTO functional variant barcode with significant allelic effects separated by cell type. 
*q<0.05 two-sided Mann Whitney U test. Haplotype and allele frequencies in the CEU 






Fig. S8. Expression of Irx3 and Irx5 during mouse hypothalamus development. 
Expression of Irx3 and Irx5 in different cell types during hypothalamus development at 
different stages: E17 (A), P0 (B), P2 (C), P10 (D), and P23 (E) (24). (F) Summary of 






Fig. S9. Generation of human hypothalamic arcuate-like neurons from iPSCs. (A) 
Bulk qPCR analysis of hypothalamic markers at four different time points during the 
differentiation of hypothalamic neurons. (B) qPCR analysis of IRX3, IRX5, IRX6, FTO, 
and RPGRIP1L expression at four different time points during the differentiation of 
hypothalamic neurons. The dashed line indicates the time point when the scRNA-seq 
assay was performed. Representative microscopy image of each differentiation stage is 
shown. Bars, 200 m (C) Schematic diagram illustrating the different stages of 
hypothalamic ARC-like neuron generation from iPSCs. (D) Overview of the 
CRISPR/Cas9 strategy to delete 36,100 bp encompassing the FTO obesity-associated 
locus in human iPSC. The gRNA-targeting sequence (gRNA) is underlined, and the PAM 
sequences are indicated in bold. Exons are represented as thick blue boxes, introns are 




region. Agarose gel shows the PCR products generated from DNA containing the 
successfully targeted FTO obesity-associated locus from iPSC genomic DNA. The 
abbreviations are: iPSCs (induced pluripotent stem cells); HPCs (hypothalamic 
progenitor cells); Early Dev (hypothalamic neurons at early development time point); 
Late Dev (hypothalamic neurons at late development time point). For qPCR analysis, the 
charts show normalized expression relative to iPSCs. Error bars represent the ±SEM from 





Fig. S10. Flowchart of scRNA-seq data analyses and UMAP embedding of merged 
scRNA-seq profiles from WT and hsFTOΔ36 human hypothalamic arcuate-like 
neurons. (A) Flowchart displaying the analytical pipeline used to evaluate the impact of 
deleting the obesity-associated interval on the expression of genes in developing 
hypothalamic neurons. (B-G) The UMAP plots show the expression of indicated genes: 
FTO, RPGRIP1L, NKX2.1, IRX3, IRX5, and POMC, respectively, along UMAP_1 and 
UMAP_2. Random subsampling of 3500 of total 91825 cells from the KNN-aggregated 




Table S5. Functional variants with significant differences in enhancer activity 
between alleles identified by MPRA and PMCA 
Lead SNP Candidate variant (dbSNP) Genomic Coordinate 
rs1558902 rs11075992 ^ * chr16:53,819,978-53,820,153 
rs1558902 rs62033403 ^ chr16:53,822,149-53,822,324 
rs1558902 rs9922619 ^ * chr16:53,831,683-53,831,858 
rs1558902 rs9937709 ^ chr16:53,820,725-53,820,900 
rs1558902 rs9940128 ^ chr16:53,800,666-53,800,841 
rs1558902 rs11642015 ☥ * chr16:53,800,870-53,801,045 
rs1558902 rs14211085 ☥ * chr16:53,802,386-53,802,561 
^ indicates variant identified by MPRA 
☥ indicates variant identified by PMCA 




Table S9. Marker genes defining cell clusters. 
Cluster name Genes 
Pluripotency SOX2, NANOG and OCT4 
Hypothalamic progenitor cells (HPC) HSP5, TAF7 and SRSF2 
Hypothalamic neurons at an early 
developmental time point (Early Dev)  
NES, SOX3, NEUROG3, ASCL1, HES1, CCND1, 
CDK4, DLL1, DLL3 
Hypothalamic neurons at a late 
developmental time point (Late Dev) 
DLX1, DLX2, DLX5, DLX6, SOX11, SOX12 
OTP, NEUROD1, STMN1/2, Nkx2-1, NPY, 
NHLH2, ARNT2, ISL1 
Radial Glia  VIM 




Table S10. Oligonucleotides and gRNA target sites used in this study. 
gRNA target sites used to generate transgenic mice 
Target 
region 
sgRNA (1) sgRNA (2) 
Irx3-/- GGAAAGCACGAGCACGCTCAAGG N/A 
Irx5-/- TGGCATTCTTCCGGTACGCGGGG CCCATGGGCGGGCAAACGCTTGG 
Irx6-/- CAGTGCTCGGCCAGAGCTGGG N/A 
mmFtoΔ20 GTTAAAATACCCTCTCATCTGGG GGTCCTTGGGATCTCCGCTTTGG 
crRNA target sites used to generate hsFTOΔ36 cell line 
Region crRNA (1) crRNA (2) 
hsFTOΔ36 CCTTTTGTAGACAGGAACCTTAC ACTCTTTTACCACTAGGTAGG 
Product length and primers sequences used to genotype transgenic mice and iPSC 
Gene Primer 5 -3 (sense) Primer 5 -3 (antisense) 
Irx3 TACCAGTACATCCGCCCTCT TGACCAGATCTTGGGCTTCT 
Irx5 AAGGACAGAGGGAAAGTGGG TCTTTAGCCAAAACGTCCGC 
Irx6 CCTTGCATAATCTCCTCTGG GCCCCATTCCATTACTTACC 
mmFtoΔ20 CCCAATTACTTTTGGCCTTTT CTCCCAGGCATAAAATTCA 
hsFTOΔ36 GGGAGGAGAGTGTGGGTTTT GTGAAGGCTTTGGATTTGGAG 
 
4C-seq PCRs oligos 
Gene 
promoter 
Reading primer Non-reading primer Enzymes 
Irx3 CTCCAGTTTTGACCCCCATG GAATCTCGGCCAATCTGTTC NlaIII/DpnII 
Irx5 CGATGCCTGCTTCTCATG   GGCATCCATCGACTCTCC NlaIII/DpnII 









Table S11. Fosmid clones used as FISH probes. 
Region Whitehead fosmids 
http://bacpac.chori.org/download
/wi1_mm9/chr8.bed 





WIBR1-0590M09 chr8:93911541-93950923 39383 
Fto/Rpgrip1
l promoter  
WIBR1-0983O10 chr8:93807527-93849628 42102 
Irx3 gene WIBR1-1206E19 chr8:94307305-94341470 34166 
Irx5 gene WIBR1-1060D04 chr8:94865335-94904882 39548 
Irx6 gene WIBR1-0901O22 chr8:95190971-95221152 30182 
FTO LB 
block del. 




Table S12. Twenty-nine genomic loci identified that passed criteria for genome-wide 
association significance. 
Index SNPs for regions with P < 5x10-8 are reported. Position – SNP position according 
to the NCBI Genome Reference Consortium human genome build 37 (GRCh37); Alleles 
– effect/no effect on genomic reference strand; EAF – effect allele frequency across all 
study participants; OR – odds ratio for the high-risk allele; CI – 95% confidence interval; 
Nearest gene – nearest gene to the index SNP 
 
rsID Chr Position 
Alleles 
(effect/no 
effect) EAF OR P value 
Nearest 
gene 
























































































































































































Additional Data (available as an excel (.xlsx) file online) 
Table S1. GO/ToppGene analysis.  
This Excel file contains a list of all up-regulated genes within cellular metabolic processes and 
regulation of hormone levels GO categories. Also, a list of the top 50 ranked diseases associated 
with these genes. 
Table S2. Sweet vs. salty preference GWAS summary statistics. 
This excel file contains the summary statistics for a GWAS performed on sweet vs. salty 
preference data collected by 23andMe, including SNP information, unadjusted P values, genomic 
control adjusted P values, and genotype counts 
Table S3. Variants tested in the Massively Parallel Reporter Assay. 
This Excel file contains all 87 SNPs tested in the MPRA assay and the functional variants with 
enhancer activity in at least three replicates tested in each cell line (3T3-L1 and HT22). 
Table S4. Significant FTO locus functional variants identified using MPRAs. 
This file contains SNPs that were identified as statistically significant enhancer modulating 
variants using a massively parallel reporter assay performed in HT22 and/or 3T3-L1 cell lines 
Table S6. PMCA accessible variants.  
This Excel file includes the variant by PMCA analysis with high score located in functionally 
conserved regions. Columns define the metrics which contribute to the PMCA overall score as 
defined in (21), with Sall in the restricted set of binding sites representing the log10 strength of 
conservation. W(TFBS), number of transcription factor (TF) binding sites; p-est (TFBS), 
estimated probability of the number of TF binding sites in the shuffled control; W(modules), 
number of TF binding modules; p-est(modules), estimated probability of the number of TF 
binding modules in the shuffled control; W (TFBS_in_modules), number of TF binding sites 
contained in modules; p-est (TFBS_in_modules), estimated probability of the number of TF 
binding sites in the shuffled control. These metrics are repeated both across all species and only 
in the restricted set (present across at least half the species). 
Table S7. DeepSEA predictions. 
This file contains all SNPs predicted by DeepSEA analysis with score < 0.01. Functional 
significance score, the -log10 p-value of a given SNP being functional, as defined in the 
DeepSEA manuscript (22). 
Table S8. Cell type specific Basset model predictions.  
This file contains all SNPs tested in the Basset model comparing the allelic activity across 170 
different cell types and tissues. We focus on the two cell types used in this study, preadipocytes 
(adipocyte_d0, ATAC-seq from immortalized adipose derived mesenchymal stem cells at day 0 
of differentiation toward adipocytes) and hypothalamic neurons (Hypothalamic neurons, ATAC-
seq from iPSC-derived hypothalamic arcuate-like neurons). Hypothalamic_Neurons_Strong 
represents the hypothalamic neuron data subset to the strongest peaks (those with a -log10 q-





Table S13. Number of cells and genes retained for the sc-RNA-seq analysis.  
This Excel file contains the number of retained cells and genes after the initial single cell RNA-
seq pre-processing, and the mitochondrial gene content for each replicate of the single cell RNA-
seq analysis. Threshold of 20% for mitochondrial gene content was applied. 
Table S14. Summary statistics for POMC-enriched cell datasets. 
This Excel file contains the number of cells across the WT and hsFTOΔ36 conditions and the 
mitochondrial content for each POMC cutoff and KNN K value. 
Table S15. Result of DE analysis for POMC-enriched cells. 
This Excel file contains the list of the logFC and adjusted P values corresponding to different 
cutoffs and different Ks for cells expressing POMC. 
Table S16. Summary statistics for cells expressing seven different neuronal marker genes. 
This Excel file contains the number of cells across the WT and hsFTOΔ36 conditions and the 
mitochondrial content for each POMC cutoff and KNN K value. Neuronal markers: ARNT2, 
NES, NEUROD1, NHLH2, NKX2.1, NPY, and OTP. 
Table S17. Result of DE analysis for cells enriched for other marker genes. 
This Excel file contains the list of the logFC and adjusted P values corresponding to different 
cutoffs and different Ks for cells expressing different neuronal markers: ARNT2, NES, 
NEUROD1, NHLH2, NKX2.1, NPY, and OTP. 
 
 
